Platelet-rich fibrin, a second-generation autologous biomaterial generated through blood centrifugation without anticoagulants, has emerged across oral and maxillofacial surgery to accelerate hard and soft tissue healing, though clinical evidence regarding specific interventions like mandibular fracture management and third molar extraction remains heterogeneous.
The Biological Rationale and Preparation of Platelet-Rich Fibrin
Platelet-rich fibrin is produced by centrifuging peripheral blood without the addition of anticoagulants. This process creates a three-dimensional fibrin scaffold enriched with platelets, leukocytes, cytokines, and essential growth factors. These bioactive molecules include platelet-derived growth factor, transforming growth factor-beta, and vascular endothelial growth factor. Together, these elements promote angiogenesis, modulate the inflammatory response, and support cell migration, proliferation, and differentiation.
Over the past decade, technical refinements have expanded the utility of the material. Optimised centrifugation protocols allow clinicians to modulate the fibrin architecture and cellular content for specific regenerative needs. For instance, low-speed centrifugation concepts yield advanced PRF and injectable PRF variants. These liquid formulations enable minimally invasive delivery and can serve as carriers for small-molecule drugs, antibiotics, and exosomes.
Applications in Maxillofacial Surgery and Fracture Management
Mandibular fractures rank among the most common maxillofacial injuries globally, typically stemming from road traffic accidents, interpersonal violence, falls, and sports-related incidents. These injuries can severely impair mastication, speech, occlusion, facial esthetics, and overall quality of life. While modern rigid and semi-rigid internal fixation techniques have transformed surgical outcomes over the past three decades, complications such as delayed bone healing, infection, and non-union still challenge clinicians.
To combat these hurdles, researchers and surgeons have turned to biological adjuncts. PRF finds widespread application across implant dentistry, periodontal regeneration, sinus augmentation, alveolar ridge preservation, and orthognathic surgery procedures including bilateral sagittal split osteotomy. More recently, practitioners have investigated PRF in the management of traumatic mandibular fractures to enhance bone healing and reduce postoperative complications.
Evaluating Evidence in Alveolar Socket Regeneration
Despite encouraging biological properties, clinical data regarding PRF efficacy remain mixed depending on the specific surgical site. A systematic review and meta-analysis evaluating the efficacy of platelet-rich fibrin after mandibular third molar extraction analyzed data from five randomized controlled trials and one controlled clinical trial, encompassing 335 extractions across 183 participants.
The analysis recorded positive results for pain, trismus, swelling, periodontal pocket depth, soft tissue healing, and the incidence of localized osteitis in several studies, though not universally. Furthermore, the qualitative and meta-analysis results showed no significant improvement in bone healing when comparing PRF-treated sockets with naturally healing sockets.
Sinus Augmentation and Antimicrobial Properties
In contrast to extraction socket findings, evidence in other specialized procedures points to distinct clinical benefits. A systematic review examining maxillary sinus augmentation demonstrates that combining autologous platelet concentrates—including platelet-rich plasma, PRF, and concentrated growth factor—with bone graft materials enhances early vascularisation and reduces postoperative inflammation. These combinations decrease the volume of autologous bone required while improving bone height and thickness.
In vitro investigations also reveal that both solid PRF membranes and liquid PRF formulations possess antibiofilm properties. Different centrifugation protocols can inhibit metabolic activity and reduce bacterial counts of key periodontopathogens such as Porphyromonas gingivalis and Fusobacterium periodonticum, underscoring the importance of protocol selection in periodontal therapies.
Standardization Challenges and Future Research Directions
The primary barrier to routine clinical incorporation remains the heterogeneity of current data. Variations in preparation protocols, application techniques, study designs, and outcome measures make direct comparison difficult across clinical trials. Consequently, researchers emphasize that future standardized randomized controlled clinical trials are required to firmly establish the effect of PRF on bone regeneration and socket healing.
Keep reading
